Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEPSI: Prognostic Impact of NLR in Breast Cancer
NCT05303129Completed
- Sponsor
- Centre François Baclesse
- Start
- May 2022
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Single-arm trial, sponsored by Centre François Baclesse. Primary endpoint: Progression-free Survival Rate at 12 months. Started May 2022; status: completed.
Beyond the preview
Go deeper on NCT05303129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05303129.